Drug Type Virus-like particle vaccine, Prophylactic vaccine, Multivalent vaccine |
Synonyms Human papillomavirus (types 16 and 18) L1 virus-like particle vaccine ( Xiamen Innovax), Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine(Escherichia coli), Recombinant human papillomavirus bivalent (type 16/18) vaccine (Xiamen Innovax) + [5] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (31 Dec 2019), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Human Papillomavirus Infection | MA | 13 May 2022 | |
Uterine Cervical Cancer | CN | 31 Dec 2019 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Human Papillomavirus Infection | Phase 3 | CN | 22 Nov 2012 | |
Human Papillomavirus Infection | Phase 3 | CN | 22 Nov 2012 | |
Infectious Diseases | Discovery | CN | 01 Jul 2017 | |
Infectious Diseases | Discovery | CN | 01 Jul 2017 | |
Uterine Cervical Cancer | Discovery | CN | 01 Jul 2017 | |
Uterine Cervical Cancer | Discovery | CN | 01 Jul 2017 |
Not Applicable | - | wddpqgferb(mzddvcukmv) = The frequencies of local injection site reactions were higher in the vaccine than placebo group; pain being the most common symptom in both groups kkobniejvm (anyykakkyd ) View more | Positive | 01 Jun 2010 |